Please use the search below. See our frequently asked questions regarding clinical trials.
Showing 1 - 10 of 168
3300 Gallows Road
Falls Church, VA 22042
This study is a US-based, prospective, double-blind, multicenter, placebo-controlled, randomized 1:1, pulmonary hypertension in LVAD patients trial.
This is a US, multicenter, placebo-controlled, HFrEF trial. Testing Entresto in patients with any history of NYHA IV symptoms. 26-week study to assess change in NT-proBNP. Sponsor: NIH HF Network.
Showing 1 - 10 of 168
Randomized Phase 2 Trial Evaluating the Addition of the IGF-lR Monoclonal Antibody Ganitumab (AMG479, NSC#750008, IND#120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 2 Trial Evaluating the Addition of the IGF-lR Monoclonal Antibody Ganitumab (AMG479, NSC#750008, IND#120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing SarcomaPazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Solt Tissue Sarcomas (PAZNTIS): A Phase 11/111 Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, ND# 118613)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Solt Tissue Sarcomas (PAZNTIS): A Phase 11/111 Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, ND# 118613)Fairfax Stem Cell Transplant Program: Autologous Transplantation Recipient and Allogeneic Related Donor Data Collection
As a transplant program we are required to collect data to document the quality of our program, maintain accreditation with national and international societies, and to enhance our understanding of stem cell transplant and the response patients have to transplant. Our transplant center sends transplant related information to US Oncology (network that we are affiliated with), the Inova Fairfax Hospital Stem Cell Transplant team, and the Center for International Blood and Bone Marrow Transplant Research (CIBMTR). For those patients having a matched unrelated donor transplant, information will be sent to the National Marrow Donor Program (NMDP). On occasion we supply statistical information to federal and state agencies and insurance companies without specific reference to individual patients.A Randomized Phase II Study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL)IND #117117
A Randomized Phase II Study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL)IND #117117Neuroblastoma Classification Biology Studies
Neuroblastoma Classification Biology Studieshttps://inova.org/clinical-trials/neuroblastoma-classification-biology-studies
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma
Inova Children's Hospital3300 Gallows Road
Falls Church, VA 22042
A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens
A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma SpecimensPARADISE MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event analysis) in post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF.Soprano
This trial seeks to evaluate the efficacy of Macitentan in patients with pulmonary hypertension after left-ventricular device (LVAD) implantation.This study is a US-based, prospective, double-blind, multicenter, placebo-controlled, randomized 1:1, pulmonary hypertension in LVAD patients trial.
LIFE
This study seeks to evaluate the effectiveness of sacubatril-valsartan (aka: Entresto) in patients with advanced heart failure.This is a US, multicenter, placebo-controlled, HFrEF trial. Testing Entresto in patients with any history of NYHA IV symptoms. 26-week study to assess change in NT-proBNP. Sponsor: NIH HF Network.